2023-2030 年按產品類型、樣品類型、技術、應用、最終用途、細分趨勢分列的美國傳染病診斷學市場規模、份額和趨勢分析報告

美國傳染病診斷市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告，美國傳染性呼吸道疾病診斷市場預計到 2030 年將達到 92 億美元，2023 年至 2030 年的複合年增長率為 -10.1%。我來了。

由於 COVID-19 測試的減少，市場預計會下降。然而，美國傳染性呼吸道疾病診斷市場仍然是技術進步、傳染性呼吸道疾病患病率增加以及開發創新產品以滿足不斷增長的市場需求的主要驅動力。預計將受到企業高研發投資的推動、政府和非政府組織。

例如，2021 年 1 月，生物醫學高級研究與發展局 (BARDA) 分別資助 QIAGEN LLC 和 DiaSorin Molecular LLC 598,000 美元和 679,000 美元，以加強 COVID-19 檢測試劑盒和儀器的開發。

用於疾病診斷的創新產品的推出有望推動美國呼吸道感染市場的增長。2020 年 4 月，Bio-Rad Laboratories, Inc. 宣佈了一種用於診斷 COVID-19 患者的免疫檢測試劑盒。這些是基於血液的免疫測定試劑盒。在最初的初步免疫測定性能中，該檢測試劑盒在 >700 名患者中表現出 >99.0% 的特異性。

PerkinElmer 還於 2022 年 9 月獲得美國 FDA 的批准，可以使用 T 細胞選擇試劑檢測試劑盒進行自動結核病檢測。該產品使用全球監管的酶聯免疫吸附點 (ELISPOT) 干擾素-γ 釋放測定來檢測潛伏性結核感染。這種 ELISPOT 測試使實驗室能夠為潛伏性結核病患者提供準確的結果。因此，傳染性呼吸道疾病診斷技術的進步正在推動市場發展。

此外，分子診斷學通過提供快速有效的結果在傳染病檢測中發揮重要作用。根據美國疾病控制和預防中心 (CDC) 的數據，2021 年結核病的估計發病率為每 10 萬人 2.4 例。同樣，根據美國胸科學會的數據，肺炎每年影響約 100 萬人，並有 50,000 人死於該病。因此，預計呼吸道感染髮病率的增加將在研究期間推動美國傳染性呼吸道疾病診斷市場。

另一方面，模糊的監管框架和高昂的診斷成本可能會在研究期間阻礙美國傳染性呼吸道疾病診斷市場。與分子和免疫檢測相關的高成本以及缺乏替代檢測產品也是導緻美國傳染性呼吸道疾病診斷產品價格上漲的主要原因。

然而，醫療保健當局正在採取措施減輕製造商的高成本負擔。從美國 FDA 獲得的用於 COVID-19 測試的 EUA 有望最大限度地降低開發成本，並加快將它們提供給更多實驗室的過程。因此，降低開發成本有望提高醫療保健專業人員和患者對該測試的負擔能力。

美國傳染性呼吸系統疾病診斷市場報告要點。

• 2022年傳染性呼吸道疾病診斷市場歸因於高使用率，耗材板塊收入佔比約為65.78%。化驗和測試套件的研究和開發的增加以及對計數器和自我測試產品以及護理點的需求增加預計將推動該細分市場的增長。
• 按樣本類型劃分，鼻咽拭子將在2022年佔據市場主導地位，預計份額為60.61%，在快速抗原檢測、直接螢光抗體、聚合酶鏈反應等各種檢測中應用廣泛，需求不斷增加。 .
• 2022 年，由於對用於診斷 COVID-19、流感、RSV 等的 RT-PCR 檢測的需求增加，分子診斷領域以 63.74% 的收入份額主導了傳染性呼吸道疾病診斷市場。
• 由於發病率高、產品批准增加以及創新產品研發增加，COVID-19 細分市場在 2022 年以 91.65% 的份額主導了美國傳染性呼吸道疾病診斷市場。然而，隨著美國正在實施的大規模疫苗接種活動降低了該病的發病率，這一比例預計到 2030 年將降至 69.97%。

目錄

第一章 調查方法和範圍

• 市場細分和範圍
  • 段範圍
• 調查方法
• 信息採購
  • 購買的數據庫：
  • GVR內部數據庫
  • 次要信息
  • 初步調查
  • 初步調查詳情
• 信息或數據分析
  • 數據分析模型
• 市場製定和驗證
• 型號詳情
  • 商品流向分析
    • 方法：產品流方法
• 調查假設
• 二級信息列表
• 縮略語表
• 目的

第二章執行摘要

• 市場快照
• 片段快照（1/3）
• 片段快照（2/3）
• 細分快照（第 3 個，共 3 個）
• 競爭格局的快照

3. 美國傳染性呼吸系統疾病診斷市場變量、趨勢和範圍

• 母公司市場展望
• 繪製滲透率和增長前景
• 市場驅動力分析
  • 美國傳染性呼吸道疾病的高流行率
  • 呼吸系統疾病檢測的技術進步
  • 增加對呼吸系統疾病檢測的研發投入
• 市場約束因素分析
  • 診斷產品的高價
  • 存在模稜兩可的監管框架
• SWOT 分析，按因素（政治和法律、經濟、技術）
• 行業分析 - 搬運工
  • 監管框架
  • 贖回場景

4 美國傳染性呼吸系統疾病診斷市場：細分分析，按產品類型，2018-2030 年（百萬美元）

• 定義和範圍
• 美國傳染性呼吸系統疾病診斷市場：產品類型變化分析
• 機器
  • 影像學檢查
  • 呼吸器
  • 其他樂器
• 消耗品
• 服務

5 美國傳染性呼吸系統疾病診斷市場：細分分析，按樣本類型，2018-2030 年（百萬美元）

• 定義和範圍
• 美國傳染性呼吸系統疾病診斷市場：樣本類型變異分析
• 唾液
• 鼻咽拭子 (Nps)
• 前鼻區
• 血液
• 其他

6 美國傳染性呼吸系統疾病診斷市場：細分分析，按技術，2018-2030 年（百萬美元）

• 定義和範圍
• 美國傳染性呼吸系統疾病診斷市場：技術波動分析
• 免疫測定
• 分子診斷
• 微生物學
• 其他技術

7 美國傳染性呼吸系統疾病診斷市場：細分分析，按應用，2018-2030（百萬美元）（'000s）

• 美國傳染性呼吸系統疾病診斷市場：應用差異分析
• COVID-19
  • COVID-19 市場，2018-2030（000 卷）
• 流感
  • 2018-2030 年流感市場（000 年代）
• 呼吸道合胞病毒
  • 呼吸道合胞病毒市場，2018-2030（000 年代）
• 結核
  • 2018-2030 年結核病市場（000 年代）
• 鏈球菌試驗
  • 鏈球菌檢測市場，2018-2030（卷 '000s）
• 其他呼吸道疾病檢查
  • 其他呼吸系統疾病檢測市場，2018-2030（卷 '000s）

8 美國傳染病呼吸系統疾病診斷市場：細分分析，按最終用途，2018-2030 年（百萬美元）

• 美國傳染性呼吸系統疾病診斷市場：最終用途變化分析
• 醫院
• 診斷實驗室
• 診所
• 其他最終用戶

9 美國傳染性呼吸系統疾病診斷市場：競爭分析

• 參會概況
• 財務績效
• 進入公司
  • 市場領導者
    • 2022 年美國傳染性呼吸系統疾病診斷市場份額分析
  • 戰略規劃
    • 擴張
    • 獲得
    • 合作
    • 產品/服務發佈
    • 合夥
    • 其他
  • 供應商情況
    • 經銷商和渠道合作夥伴名單
    • 主要客戶
• 競爭儀錶盤分析
  • 民營企業
    • 初創公司/技術顛覆者/創新者名單
    • 區域網絡圖
    • Abbott
    • Koninklijke Philips N.V.
    • Siemens Healthcare GmbH
    • BIOMERIEUX
    • Danaher
    • QIAGEN
    • BD
    • F. Hoffmann-La Roche Ltd
    • Quidel Corporation
    • Thermo Fisher Scientific, Inc.

U.S. Infectious Respiratory Disease Diagnostics Market Growth & Trends:

The U.S. infectious respiratory disease diagnostics market is expected to reach USD 9.20 billion by 2030, registering a CAGR of -10.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to decline due to the decrease in COVID-19 testing. However, the U.S. infectious respiratory disease diagnostics market is expected to be driven by technological advancements, an increase in the prevalence of infectious respiratory diseases, and high R&D investments by the key players, government, & NGOs to develop novel & innovative products to address the increased market demand.

For instance, in January 2021, Biomedical Advanced Research and Development Authority (BARDA) funded USD 598,000 and USD 679,000 to QIAGEN LLC and DiaSorin Molecular LLC, respectively to enhance the development of COVID-19 test kits and instruments.

The introduction of innovative products used for disease diagnosis is anticipated to fuel the U.S. respiratory infectious disease market growth. In April 2020, Bio-Rad Laboratories, Inc. introduced immunoassay test kits for the diagnosis of COVID-19 patients. These were blood-based immunoassay test kits. In the initial preliminary performance of the immunoassay, the test kit demonstrated a specificity of more than 99.0% in more than 700 patients.

In addition, PerkinElmer, Inc. received approval from the U.S. FDA for the use of a T-cell select reagent test kit for the automation of its tuberculosis spot in September 2022. It uses a globally regulated enzyme-linked immunosorbent spot (ELISPOT) interferon-gamma release assay to detect latent tuberculosis infection. This ELISPOT test enables laboratories to offer accurate results to patients with latent tuberculosis. Thus, technological advancements in infectious respiratory disease diagnostics are fueling the market.

Moreover, molecular diagnostics play an important role in infectious disease testing by offering quick & effective results. According to the Centers for Disease Prevalence and Prevention (CDC), the estimated incidence rate of tuberculosis was 2.4 cases per 100,000 populations as of 2021. Similarly, according to the American Thoracic Society, pneumonia affects around 1.0 million people annually, and 50,000 die from this disease. Thus, the increasing incidence of respiratory infections is expected to drive the U.S. infectious respiratory disease diagnostics market during the study period.

On the other hand, the presence of ambiguous regulatory frameworks and high prices of diagnostics products may hamper the U.S. infectious respiratory disease diagnostics market during the study period. High costs related to molecular & immunoassay tests and lack of alternative testing products are the other major reasons for increased prices of infectious respiratory disease diagnostic products in the U.S.

However, healthcare authorities have taken steps to reduce the burden of high costs on manufacturers. EUA received from the U.S. FDA for COVID-19 tests is expected to minimize development costs and accelerate the process to increase the availability at more testing sites. Hence, a decrease in development costs is anticipated to increase the affordability of tests for healthcare providers and patients.

U.S. Infectious Respiratory Disease Diagnostics Market Report Highlights:

• The consumables segment dominated the infectious respiratory illness diagnostics market in 2022 with a revenue share of around 65.78%, which can be attributed to high usage rates. An increase in R&D for assays and testing kits, coupled with a rise in demand for the point-of-care in addition to the counter & self-test products is expected to drive the segment growth

• Based on the sample type, the market was dominated by nasopharyngeal swabs with an estimated share of 60.61% in 2022, due to wide applications in conducting various tests such as rapid antigen detection tests, direct fluorescent antibody, and polymerase chain reaction coupled with increased demand

• In 2022, the molecular diagnostics segment dominated the infectious respiratory disease diagnostics market with a revenue share of 63.74%, due to the increased demand for RT-PCR tests used for the diagnosis of COVID-19, influenza, RSV, and others

• The COVID-19 segment dominated the U.S. infectious respiratory disease diagnostics market with a share of 91.65% in 2022, due to the high incidence, increased product approvals, and rise in R&D pertaining to innovative products. However, its share is expected to decline to 69.97% by 2030 due to the mass vaccination drives being conducted in the U.S., which, in turn, will reduce the rate of diseases

Table of Contents

Chapter 1 Research Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Scope
  • 1.1.2 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List Of Secondary Sources
• 1.9 List Of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot (1/3)
• 2.3 Segment Snapshot (2/3)
• 2.4 Segment Snapshot (3/3)
• 2.5 Competitive Landscape Snapshot

Chapter 3 U.S. Infectious Respiratory Disease Diagnostics Market Variables, Trends, And Scope

• 3.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Market Driver Analysis
  • 3.3.1 High Prevalence Of Infectious Respiratory Diseases In U.S.
  • 3.3.2 Technological Advancement In Respiratory Disease Testing
  • 3.3.3 Rising R&D Investments In Respiratory Disease Testing
• 3.4 Market Restraint Analysis
  • 3.4.1 High Prices Of Diagnostic Products
  • 3.4.2 Presence Of Ambiguous Regulatory Framework
• 3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
• 3.6 Industry Analysis - Porter's
  • 3.6.1 Regulatory Framework
  • 3.6.2 Reimbursement Scenario

Chapter 4 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Product Type, 2018 - 2030 (USD Million)

• 4.1 Definitions And Scope
• 4.2 U.S. Infectious Respiratory Disease Diagnostics Market: Product Type Movement Analysis
• 4.3 Instruments
  • 4.3.1 Instruments Market, 2018 - 2030 (USD Million)
  • 4.3.2 Imaging Tests
    • 4.3.2.1 Imaging Tests Market, 2018 - 2030 (USD Million)
  • 4.3.3 Respiratory Measurement Devices
    • 4.3.3.1 Respiratory Measurement Devices Market, 2018 - 2030 (USD Million)
  • 4.3.4 Other Instruments
    • 4.3.4.1 Other Instruments Market, 2018 - 2030 (USD Million)
• 4.4 Consumables
  • 4.4.1 Consumables Market, 2018 - 2030 (USD Million)
• 4.5 Services
  • 4.5.1 Services Market, 2018 - 2030 (USD Million)

Chapter 5 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Sample Type, 2018 - 2030 (USD Million)

• 5.1 Definitions & Scope
• 5.2 U.S. Infectious Respiratory Disease Diagnostics Market: Sample Type Movement Analysis
• 5.3 Saliva
  • 5.3.1 Saliva Market, 2018 - 2030 (USD Million)
• 5.4 Nasopharyngeal Swabs (Nps)
  • 5.4.1 Nasopharyngeal Swabs (Nps) Market, 2018 - 2030 (USD Million)
• 5.5 Anterior Nasal Region
  • 5.5.1 Anterior Nasal Region Market, 2018 - 2030 (USD Million)
• 5.6 Blood
  • 5.6.1 Blood Market, 2018 - 2030 (USD Million)
• 5.7 Others
  • 5.7.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Technology, 2018 - 2030 (USD Million)

• 6.1 Definitions And Scope
• 6.2 U.S. Infectious Respiratory Disease Diagnostics Market: Technology Movement Analysis
• 6.3 Immunoassay
  • 6.3.1 Immunoassay Market, 2018 - 2030 (USD Million)
• 6.4 Molecular Diagnostics
  • 6.4.1 Molecular Diagnostics Market, 2018 - 2030 (USD Million)
• 6.5 Microbiology
  • 6.5.1 Microbiology Market, 2018 - 2030 (USD Million)
• 6.6 Other Technologies
  • 6.6.1 Other Technologies Market, 2018 - 2030 (USD Million)

Chapter 7 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Application, 2018 - 2030 (USD Million) ('000s)

• 7.1 U.S. Infectious Respiratory Disease Diagnostics Market: Application Movement Analysis
• 7.2 Covid-19
  • 7.2.1 Covid-19 Market, 2018 - 2030 (USD Million)
  • 7.2.2 Covid-19 Market, 2018 - 2030 (Volume '000s)
• 7.3 Influenza
  • 7.3.1 Influenza Market, 2018 - 2030 (USD Million)
  • 7.3.2 Influenza Market, 2018 - 2030 (Volume '000s)
• 7.4 Respiratory Syncytial Virus
  • 7.4.1 Respiratory Syncytial Virus Market, 2018 - 2030 (USD Million)
  • 7.4.2 Respiratory Syncytial Virus Market, 2018 - 2030 (Volume '000s)
• 7.5 Tuberculosis
  • 7.5.1 Tuberculosis Market, 2018 - 2030 (USD Million)
  • 7.5.2 Tuberculosis Market, 2018 - 2030 (Volume '000s)
• 7.6 Streptococcus Testing
  • 7.6.1 Streptococcus Testing Market, 2018 - 2030 (USD Million)
  • 7.6.2 Streptococcus Testing Market, 2018 - 2030 (Volume '000s)
• 7.7 Other Respiratory Disease Testing
  • 7.7.1 Other Respiratory Disease Testing Market, 2018 - 2030 (USD Million)
  • 7.7.2 Other Respiratory Disease Testing Market, 2018 - 2030 (Volume '000s)

Chapter 8 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

• 8.1 U.S. Infectious Respiratory Disease Diagnostics Market: End-Use Movement Analysis
• 8.2 Hospitals
  • 8.2.1 Hospitals Market, 2018 - 2030 (USD Million)
• 8.3 Diagnostic Laboratories
  • 8.3.1 Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
• 8.4 Physician Offices
  • 8.4.1 Physician Offices Market, 2018 - 2030 (USD Million)
• 8.5 Other End Users
  • 8.5.1 Other End-Users Market, 2018 - 2030 (USD Million)

Chapter 9 U.S. Infectious Respiratory Disease Diagnostics Market: Competitive Analysis

• 9.1 Participants' Overview
• 9.2 Financial Performance
• 9.3 Participant Categorization
  • 9.3.1 Market Leaders
    • 9.3.1.1 U.S. Infectious Respiratory Disease Diagnostics Market Share Analysis, 2022
  • 9.3.2 Strategy Mapping
    • 9.3.2.1 Expansion
    • 9.3.2.2 Acquisition
    • 9.3.2.3 Collaborations
    • 9.3.2.4 Product/Service Launch
    • 9.3.2.5 Partnerships
    • 9.3.2.6 Others
  • 9.3.3 Vendor Landscape
    • 9.3.3.1 List Of Distributors And Channel Partners
    • 9.3.3.2 Key Customers
• 9.4 Competitive Dashboard Analysis
  • 9.4.1 Private Companies
    • 9.4.1.1 List of Emerging Companies/Technology Disruptors/ Innovators
    • 9.4.1.2 Regional Network Map include:
    • 9.4.1.2.1 Abbott
    • 9.4.1.2.2 Koninklijke Philips N.V.
    • 9.4.1.2.3 Siemens Healthcare GmbH
    • 9.4.1.2.4 BIOMERIEUX
    • 9.4.1.2.5 Danaher
    • 9.4.1.2.6 QIAGEN
    • 9.4.1.2.7 BD
    • 9.4.1.2.8 F. Hoffmann-La Roche Ltd
    • 9.4.1.2.9 Quidel Corporation
    • 9.4.1.2.10 Thermo Fisher Scientific, Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 CPT codes reimbursement of diagnostic tests
• Table 4 U.S. infectious respiratory disease diagnostics market by, product type, 2018 - 2030 (USD Million)
• Table 5 U.S. infectious respiratory disease diagnostics market by, sample type, 2018 - 2030 (USD Million)
• Table 6 U.S. infectious respiratory disease diagnostics market by, technology, 2018 - 2030 (USD Million)
• Table 7 U.S. infectious respiratory disease diagnostics market by, application, 2018 - 2030 (USD Million)
• Table 8 U.S. infectious respiratory disease diagnostics market by, end-use, 2018 - 2030 (USD Million)
• Table 9 Participant's overview
• Table 10 Financial performance
• Table 11 Key companies undergoing expansions
• Table 12 Key companies undergoing acquisitions
• Table 13 Key companies undergoing collaborations
• Table 14 Key companies launching new products/services
• Table 15 Key companies undergoing partnerships
• Table 16 Key companies undertaking other strategies

List of Figures

• Fig. 1 U.S. Infectious Respiratory Disease Diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (By product & sample type)
• Fig. 11 Segment snapshot (By technology type & end-use type)
• Fig. 12 Segment snapshot (By application)
• Fig. 13 Competitive landscape snapshot
• Fig. 14 Penetration and growth prospect mapping
• Fig. 15 U.S. infectious respiratory disease diagnostics market driver impact
• Fig. 16 Number of new tuberculosis cases from 2018-2021, in the U. S.
• Fig. 17 Incidence rate trend of tuberculosis from 2018-2021
• Fig. 18 U.S. infectious respiratory disease diagnostics market restraint impact
• Fig. 19 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• Fig. 20 Porter's Five Forces Analysis
• Fig. 21 U.S. healthcare reimbursement and financing structure
• Fig. 22 U.S. infectious respiratory disease diagnostics product type outlook: Key takeaways
• Fig. 23 Infectious respiratory disease diagnostics market: Product type movement analysis (USD Million)
• Fig. 24 Instruments market, 2018 - 2030 (USD Million)
• Fig. 25 Imaging tests market, 2018 - 2030 (USD Million)
• Fig. 26 Respiratory measurement devices market, 2018 - 2030 (USD Million)
• Fig. 27 Other instruments market, 2018 - 2030 (USD Million)
• Fig. 28 Consumables market, 2018 - 2030 (USD Million)
• Fig. 29 Services market, 2018 - 2030 (USD Million)
• Fig. 30 U.S. Infectious respiratory disease diagnostics Sample type outlook: Key takeaways
• Fig. 31 U.S. infectious respiratory disease diagnostics market: Sample type movement analysis (USD Million)
• Fig. 32 Saliva market, 2018 - 2030 (USD Million)
• Fig. 33 Nasopharyngeal swabs (NPS) market, 2018 - 2030 (USD Million)
• Fig. 34 Anterior Nasal Region market, 2018 - 2030 (USD Million)
• Fig. 35 Blood market, 2018 - 2030 (USD Million)
• Fig. 36 Others market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. infectious respiratory disease diagnostics technology outlook: Key takeaways
• Fig. 38 U.S. infectious respiratory disease diagnostics market: Technology movement analysis (USD Million)
• Fig. 39 Immunoassay market, 2018 - 2030 (USD Million)
• Fig. 40 Molecular diagnostics market, 2018 - 2030 (USD Million)
• Fig. 41 Microbiology market, 2018 - 2030 (USD Million)
• Fig. 42 Other technologies market, 2018 - 2030 (USD Million)
• Fig. 43 U.S. infectious respiratory disease diagnostics application outlook: Key takeaways
• Fig. 44 U.S. infectious respiratory disease diagnostics application outlook: Key takeaways (Volume 000)
• Fig. 45 U.S. infectious respiratory disease diagnostics market: Application movement analysis (USD Million)
• Fig. 46 U.S. infectious respiratory disease diagnostics market: Application movement analysis (Volume, '000s)
• Fig. 47 COVID-19 market, 2018 - 2030 (USD Million)
• Fig. 48 COVID-19 market, 2018 - 2030 (Volume '000s)
• Fig. 49 Influenza market, 2018 - 2030 (USD Million)
• Fig. 50 Influenza market, 2018 - 2030 (Volume '000s)
• Fig. 51 Respiratory syncytial virus market, 2018 - 2030 (USD Million)
• Fig. 52 Respiratory syncytial virus market, 2018 - 2030 (Volume '000s)
• Fig. 53 Tuberculosis market, 2018 - 2030 (USD Million)
• Fig. 54 Tuberculosis market, 2018 - 2030 (Volume '000s)
• Fig. 55 Streptococcus testing market, 2018 - 2030 (USD Million)
• Fig. 56 Streptococcus testing market, 2018 - 2030 (Volume '000s)
• Fig. 57 Other respiratory disease testing market, 2018 - 2030 (USD Million)
• Fig. 58 Other respiratory disease testing market, 2018 - 2030 (Volume '000s)
• Fig. 59 U.S. Infectious respiratory disease diagnostics end-use outlook: Key takeaways
• Fig. 60 U.S. infectious respiratory disease diagnostics market: End-use movement analysis (USD Million)
• Fig. 61 Hospitals market, 2018 - 2030 (USD Million)
• Fig. 62 Diagnostic laboratories market, 2018 - 2030 (USD Million)
• Fig. 63 Physician offices market, 2018 - 2030 (USD Million)
• Fig. 64 Other end-users' market, 2018 - 2030 (USD Million)
• Fig. 65 Market participant categorization
• Fig. 66 U.S. infectious respiratory disease diagnostics market share analysis, 2022
• Fig. 67 Strategic framework
• Fig. 68 Company market position analysis
• Fig. 69 Regional network map